The US influenza diagnostic market size was USD 1.60 Billion in 2022 and is likely to reach USD 2.73 Billion by 2031, expanding at a CAGR of 6.1% during 2023–2031. The growth of the market is attributed to the wide prevalence of influenza and other flu diseases in the US.
Influenza, as a type of flu disease, is caused by the influenza virus and is divided into three groups. The three types of influenza virus are Type A, Type B, and Type C, which are distinguished by their surface proteins, neuraminidase (NA), and hemagglutinin (HA). Since influenza is an infectious disease and transmitted through droplets from mouth, it can be easily spread in public places by infected patients, who often serve as disease carriers.
Introduction of increased government programs aiming at facilitating effective diagnosis have made it easier to obtain over-the-counter (OTC) tests that are user-friendly and help in timely diagnosis. For example, in 2018, the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with Diassess Inc. and Cue Health, Inc. to create testing kits for influenza diagnosis.
Moreover, several OTC medications are also available that are only intended for the use in home care environments, allowing patients to perform self for the screening of the disease infection. As per the deal, Cue Health, Inc. and Diassess Inc. each were agreed to receive USD 14 million from BARDA for the advanced production of diagnostic tests for influenza B and A virus, which were categorized as OTC products.
According to the Centers for Disease Control and Prevention (CDC), people attaining the aged of 65 years and above accounted for 58% of influenza-related hospitalizations in the US in 2018. Moreover, kids, pregnant women, and other groups of patients with a variety of chronic conditions are among those who are at high risk of contracting the flu virus.
In April 2020, the CDC confirmed 186 influenza-related pediatric deaths in the country. The organization further stated that in 2019, 49.1% of the pregnant women had received the flu vaccine and 38% received both the flu and the Tdap, which included Tetanus, Diphtheria, and Pertussis vaccines.
Market Trends, Drivers, Restraints, and Opportunities
-
Rising geriatric population and pregnant women who are more risk and have a higher chance of contracting influenza are expected to boost the market growth.
-
Rapid development of self-help diagnostic devices and user-friendly testing kits to detect the flu virus is projected to drive the market expansion.
-
Wide adoption of advanced technology and favorable government policies encouraging the manufacturing diagnostic devices in the country is another key drivers propelling the market.
-
Requirement of the high standardization of research findings and the high installment cost of diagnostic instruments are key challenges that can hamper the market growth.
-
Ongoing R&D activities from the key players to development advanced diagnostic techniques are offering major opportunities for the market development.
Scope of the Report
The report on the US influenza diagnostic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Influenza Diagnostic Market - US Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Test Types (RIDT, RT-PCR, Cell Culture, and Others) and End-users (Hospital, Laboratories, and POCT)
|
|
Country Scope
|
The US
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Alere; 3M Health Care; Meridian Bioscience, Inc., Becton, Dickinson and Company; Quidel Corporation; Meridian Bioscience, Inc.; SA Scientific, Roche Diagnostics Corporation; Thermo Fisher Scientific Inc.; and Sekisui Diagnostics.
|
Market Segment Insights
RIDT segment is expected to hold a dominant share
Based on test types, the US influenza diagnostic market is divided into RIDT, RT-PCR, cell culture, and others. The RIDT segment is expected to account for a key share of the market in the coming years owing to widely accessible of the testing type, making them easier to diagnose. RDIT is also recommended by World Health Organization (WHO) for influenza diagnosis as it is moderately complex, responsive, precise, and reliable.
Meanwhile, cell culture is an old and effective method of diagnosing the flu that normally takes 3 to 10 days to produce accurate results after sampling. Immunoassay kits are another way to diagnose the disease and is expected to be fueled by an increase in immunoassays provided by market players.
Becton, Dickinson and Company, for example, provides the BD Veritor Plus device, a wireless immunoassay for the detection of influenza A and B. Due of its integrated program and efficient interpretation of different infectious diseases, this product has reliable outputs of RDITs in terms of sensitivity and specificity.
POCT is expected to boost market growth
On the basis of end-users, the market is divided into hospitals, laboratories, and POCT. Due to an increase in the prevalence of the flu diseases in the US, the hospitals segment is projected to hold a large market share in the coming years. According to the CDC, there were 30,453 laboratory-confirmed influenza-related hospitalizations in the US in 2020, accounting for 9% of the population.
As a result, this had led to an increase in hospitalization. With advanced technologies developed by market players, the POCT segment is expected to fuel the market growth during the forecast period. For example, bioMerieux SA's BIONEXIA Influenza A+B, a rapid test for the detection of influenza A and B viruses in humans, are using a nasopharyngeal sample, which is an easy-to-use, cost-effective, and reliable POCT product.
New technological developments in POCT kits that allow error-free results are expected to boost the market. The real-time PCR technique is often used in laboratory research. Accurate performance, sensitivity, cost-effectiveness, and the opportunity to monitor several samples at once are some of the benefits of this research.
Segments
The US influenza diagnostic market has been segmented on the basis of
Test Types
- RIDT
- RT-PCR
- Cell Culture
- Others
End-users
- Hospital
- Laboratories
- POCT
Country
Key Players
- Alere
- 3M Health Care
- Meridian Bioscience, Inc.
- Becton
- Dickinson and Company
- Quidel Corporation
- Meridian Bioscience, Inc.
- SA Scientific
- Roche Diagnostics Corporation
- Thermo Fisher Scientific Inc.
- Sekisui Diagnostics
Competitive Landscape
Some of the key players operating in the US influenza diagnostic market are Alere; 3M Health Care; Meridian Bioscience, Inc., Becton, Dickinson and Company; Quidel Corporation; Meridian Bioscience, Inc.; SA Scientific, Roche Diagnostics Corporation; Thermo Fisher Scientific Inc.; and Sekisui Diagnostics.
The introduction of technologically advanced products by major market players is expected to have a positive effect on market growth. For example, Alere Inc. obtained 510 (k) marketing approval from the US Food and Drug Administration in 2017 for its Alere I Influenza A & B 2 test, which is used to diagnose influenza B & A infection in adults and children. This product is a high-specificity rapid molecular assay that provides reliable results in a short period of time.
Meridain Bioscience, Inc. also announced the addition of immunoCard STAT Flu A & B to its immunoCard STAT product line. Within 10-15 minutes, this product can detect the presence of influenza A and B in nasopharyngeal and nasal swabs. As a result, market growth is expected to be fueled by an increase in the number of products launched by leading market players over the forecast period.
Request For Customization
Enquiry Before Buying
Speak With Analyst
